

7. R&D Pipeline

	Stage	Theme	Target	Dosage Form	Characteristics	Next Step
1	Approved	XELSTRYM(ATS)	USA	Patch	Attention Deficit Hyperactivity Disorder(ADHD)	To be launched in FY22
2	Filed	HP-3150	JPN	Patch	Low back pain Humeroscapular periarthritis Cervico-omo-brachial syndrome Tenosynovitis	To be approved in FY22
3	Filed being prepared	HP-5070	JPN	Transdermal	Primary palmar hyperhidrosis	To be filed in FY22
4	Phase3	HP-5000	USA	Patch	Osteoarthritis of the knee	To be filed in FY23

※ Yellow-highlighted parts are changes from the previous announcement made on Jan.13th,2022